Author:

Keywords:

Guideline, lymphoma, MGUS, Waldenstrom, lympho-plasmacytic lymphoma, Science & Technology, Life Sciences & Biomedicine, Medicine, General & Internal, General & Internal Medicine, LYMPHOPLASMACYTIC LYMPHOMA/WALDENSTROM MACROGLOBULINEMIA, IGM MONOCLONAL GAMMOPATHY, INTERNATIONAL WORKSHOP, CHOP-R, RECOMMENDATIONS, RITUXIMAB, THERAPY, TRIAL, UPDATE, STRATIFICATION, Antineoplastic Combined Chemotherapy Protocols, Bone Marrow, Humans, Immunologic Factors, Monoclonal Gammopathy of Undetermined Significance, Plasmapheresis, Waldenstrom Macroglobulinemia, HOVON Multiple Myeloma Working Party, HOVON Lymphoma Working Party

Abstract:

On behalf of the lymphoma and multiple myeloma working parties of the Dutch/Belgian Haemato-Oncology Foundation for Adults in The Netherlands (HOVON), we present a guideline for diagnosis and management of Waldenström's macroglobulinemia (WM). Considering the indolent behaviour and heterogeneous clinical presentation of WM, it is crucial to determine the right indications for treatment, as well as to individualise therapeutic options. There are significant differences from the approach to multiple myeloma or the treatment of other indolent non-Hodkgin lymphomas, and these results cannot always be extrapolated. There is a lack of large clinical trials due to the low incidence of WM. Based on the available data, we provide a practical diagnostic classification, as well as recommendations for first-line therapy and options for treating relapsed disease. Some typical clinical features of WM, such as autoimmune phenomena and 'IgM flare' after rituximab treatment, are highlighted. A more elaborate version of this guideline was published in the 'Nederlands Tijdschrift voor Hematologie' (Dutch Journal for Hematology) September 2012.